Geron Corp (NASDAQ: GERN) reported Q2 EPS of ($0.08), $0.07 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $131 thousand versus the consensus estimate of $50 thousand.

“Geron has continued to execute on its 2019 development plans,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer. “In the third quarter, we completed the transition of the imetelstat program back to Geron, and we announced that the FDA granted Fast Track designation to imetelstat in relapsed/refractory myelofibrosis. In October, we announced the first patient dosed in the IMerge Phase 3 trial, and we are currently focused on patient recruitment and enrollment. Another priority is to prepare for an End of Phase 2 meeting with the FDA to discuss potential late-stage development of imetelstat in relapsed/refractory MF. All of these activities support the development of imetelstat as a potential treatment to address unmet medical needs in hematologic myeloid malignancies.”

For earnings history and earnings-related data on Geron Corp (GERN) click here.